Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2025 (2025-03-31): -280.30%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-212.49%
RETURN ON EQUITY (ROE) AVG 3Y
-181.28%
RETURN ON EQUITY (ROE) AVG 5Y
-140.92%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
electroCore, Inc.
Market Cap
$92.14M
Return on Equity (ROE)
N/A
TTM Avg
-212.49%
3Y Avg
-181.28%
5Y Avg
-140.92%
Market Cap
$92.90M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$90.41M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$88.21M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$86.43M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.75M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$87.48M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$98.00M
Return on Equity (ROE)
-461.14%
TTM Avg
-233.39%
3Y Avg
-227.67%
5Y Avg
-163.94%
Market Cap
$96.05M
Return on Equity (ROE)
-103.31%
TTM Avg
-140.03%
3Y Avg
-67.31%
5Y Avg
-49.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $92.14M | N/A | -212.49% | -181.28% | -140.92% |
| Biomea Fusion, Inc. (BMEA)vs › | $92.90M | -268.09% | -238.76% | -155.55% | -124.74% |
| Equillium, Inc. (EQ)vs › | $90.41M | -32.15% | -60.32% | -93.79% | -79.41% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.51% | -5.84% | -10.75% | -7.81% |
| Conexeu Sciences Inc. (CNXU)vs › | $86.43M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.75M | 45.93% | 16.96% | -19.36% | -13.87% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.48M | -150.95% | -77.89% | -62.90% | -47.80% |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $98.00M | -461.14% | -233.39% | -227.67% | -163.94% |
| Korro Bio, Inc. (KRRO)vs › | $96.05M | -103.31% | -140.03% | -67.31% | -49.97% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.18M | -85.65% | -57.41% | -45.73% | -8.61% |
ROE
N/A
ROA
-86.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | -280.30% |
| 2024-12-31 | -157.56% |
| 2024-09-30 | -134.21% |
| 2024-06-30 | -124.00% |
| 2024-03-31 | -366.39% |
| 2023-12-31 | -253.08% |
| 2023-09-30 | -186.52% |
| 2023-06-30 | -311.62% |
| 2023-03-31 | -189.47% |
| 2022-12-31 | -129.71% |
| 2022-09-30 | -96.01% |
| 2022-06-30 | -73.08% |
| 2022-03-31 | -54.74% |
| 2021-12-31 | -46.98% |
| 2021-09-30 | -45.93% |
| 2021-06-30 | -79.60% |
| 2021-03-31 | -80.42% |
| 2020-12-31 | -102.18% |
| 2020-09-30 | -90.89% |
| 2020-06-30 | -152.52% |
| 2020-03-31 | -229.53% |
| 2019-12-31 | -186.09% |
| 2019-09-30 | -164.21% |
| 2019-06-30 | -132.54% |
| 2019-03-31 | -114.56% |
| 2018-12-31 | -85.16% |
| 2018-09-30 | -57.66% |
| 2018-06-30 | -48.91% |
